Barclays Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $3.00

Revance Therapeutics (NASDAQ:RVNC – Free Report) had its price target trimmed by Barclays from $7.00 to $3.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. Several other analysts have also issued reports on the stock. StockNews.com began coverage on shares […]

Leave a Reply

Your email address will not be published.

Previous post HashiCorp (NASDAQ:HCP) Earns Hold Rating from Analysts at StockNews.com
Next post CVD Equipment (NASDAQ:CVV) Now Covered by StockNews.com